Skip to main content

Regino Gonzalez-Peralta, MD

Regino Gonzalez-Peralta, MD

Pediatric Gastroenterologist

Pediatrics

Regino Gonzalez-Peralta

Overview

Regino Gonzalez-Peralta, MD, is a board-certified pediatric gastroenterologist with additional board certification in pediatric transplant hepatology. Prior to joining AdventHealth Medical Group, he served as a tenured pediatrics professor, assistant dean and director of pediatric hepatology at the University of Florida and concurrently served as a pediatric hepatologist at Arnold Palmer Hospital for Children. A native of Cuba, Dr. Gonzalez-Peralta grew up in Miami and attended Cornell University before pursuing his medical degree at the Universidad Central del Este (Dominican Republic). He undertook his pediatrics residency at Cook County Hospital in Chicago, and continued as Senior Resident and Co-Chief Resident at the University of Florida before being selected for a prestigious fellowship in pediatric gastroenterology. His clinical and research interests include childhood HBV and HCV infection, pediatric liver transplant, Wilson disease, alpha 1 antitrypsin deficiency, pediatric hepatology and clinical trials.

Articles

North American Biliary Stricture Management Strategies in Children After Liver Transplantation: A Multicenter Analysis From the Society of Pediatric Liver Transplantation (SPLIT) Registry

LIVER TRANSPLANTATION

2022

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study

HEPATOLOGY

2021

A Learning Health System for Pediatric Liver Transplant: The Starzl Network for Excellence in Pediatric Transplantation

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

2021

Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

2020

Bipolar disorder in patients with Wilson disease

JOURNAL OF PSYCHOSOMATIC RESEARCH

2020

Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

2020

EFFECT OF LIVER DISEASE, NEUROLOGICAL DISEASE AND MENTAL HEALTH ISSUES ON QUALITY OF LIFE IN PATIENTS WITH WILSON DISEASE

GUT

2020

SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR (SOF/VEL) IN PEDIATRIC PATIENTS 6 TO < 18 YEARS OLD WITH CHRONIC HEPATITIS C (CHC) INFECTION

GUT

2020

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to < 12 Years With Hepatitis C Virus Genotype 2 or 3 Infection

HEPATOLOGY

2019

A learning health network for pediatric liver transplantation: Inaugural meeting report from the Starzl Network for Excellence in Pediatric Transplantation

PEDIATRIC TRANSPLANTATION

2019

Education & Training

Education

Universidad Central Del Este

Residency

John H. Stroger, Jr, Hospital of Cook County - Graduate Education
Cook County Health

Fellowship

University of Florida
University of Florida - College of Medicine

Board Certifications

American Board of Pediatrics

Associated Clinical Trials

NCT02486406

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)

Icon for trial | AM3 An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1

The purpose of this study is to determine drug doses for children who are at ages 3 to 17 years old at the time of enrollment and to see if the study drugs are safe and able to clear the HCV from the body.

NCT03905330

MRX-502: Randomized Double-blind placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC

Icon for trial | MRX-502 MRX-502: Randomized Double-blind placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC

This study is currently enrolling.

The goal of this study is to determine whether maralixibat is safe and effective in the treatment of Progressive Familial Intrapeatic Cholestasis (PFIC). Currently, there is no approved treatment for PFIC and available medical ...